Trials / Completed
CompletedNCT00351767
A Study to Assess the Effect of Topical Recombinant Human Vascular Endothelial Growth Factor for Induction of Healing of Diabetic Foot Ulcers
A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Effect of Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Diabetic Foot Ulcers
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 170 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase II, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of three different doses of topically applied telbermin in subjects ≥ 18 years old with diabetic foot ulcers. Approximately 160 adult subjects with Type 1 or Type 2 diabetes mellitus will be enrolled at approximately 40 investigational sites in the United States and Canada.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | placebo | Topically applied |
| DRUG | telbermin | Topically applied |
Timeline
- Start date
- 2006-01-01
- Primary completion
- 2008-01-01
- First posted
- 2006-07-13
- Last updated
- 2013-01-25
Source: ClinicalTrials.gov record NCT00351767. Inclusion in this directory is not an endorsement.